Daniel Brungs

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

Christopher J. Sweeney, Andrew Martin, Martin R. Stockler et al. · The Lancet Oncology · 2023 · 175 citations

Urology, Oncology, Genitourinary Cancer +7

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares et al. · Journal of Clinical Oncology · 2024 · 130 citations · Full text

Establishment of novel long-term cultures from EpCAM positive and negative circulating tumour cells from patients with metastatic gastroesophageal cancer

Daniel Brungs, Elahe Minaei, Ann‐Katrin Piper et al. · Scientific Reports · 2020 · 47 citations · Full text

Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer

Daniel Brungs, Morteza Aghmesheh, Paul de Souza et al. · Clinical Colorectal Cancer · 2018 · 45 citations

Oncology, Elderly Patients, Gastrointestinal Oncology +6

Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma

K. Connolly, Daniel Brungs, E. Szeto et al. · Current Oncology · 2013 · 42 citations · Full text

Tumour Resistance, Medicine, Pharmacology +14